Home → Symptoms & Diagnosis → Types of Breast Cancer → Recurrent and Metastatic Breast Cancer → Ask-the-Expert Conferences: Metastatic Breast Cancer → October 2007: Living with Metastatic Breast Cancer → New treatment schedule for Xeloda?

New treatment schedule for Xeloda?

Page last modified on: August 1, 2008

Question from Joan: I've been on Xeloda for a year now and it is working, but the side effects are somewhat debilitating — hand-foot syndrome. What do you consider to be a good schedule for the drug — 7 days on, 7 days off at a higher dose? I understand that this is a new protocol.: Answer —Larry Norton, M.D.: Yes, that's a treatment that we've developed at Memorial Sloan-Kettering. The conventional schedule for Xeloda (chemical name: capecitabine) is 14 days on and 7 days off. However, by analyzing lab experiments, we have determined that most of the cancer killing activity of the drug is in the first 7 days of exposure. Hence we have explored 7 days on and 7 days off instead of 14 days on and 7 days off. This allows a higher dose to be administered safely, and seems to remarkably reduce the incidence of hand-foot syndrome. Currently this regimen is being tested in various settings; however, because of the reduction in toxicity many oncologists are already using the 7 on/7 off schedule as their preferred method of administration. The important thing is to stay away from the drug until the hand-foot heals completely. You can go to other anti-cancer medications for weeks or months until the hand-foot syndrome heals, and then go back to the Xeloda with the new schedule and get anti-cancer activity with reduced side effects.

On Wednesday, October 17, 2007 our Ask-the-Expert Online Conference was called Living with Metastatic Breast Cancer. Larry Norton, M.D. and moderator Marisa Weiss, M.D. answered your questions about managing day-to-day life with metastatic breast cancer.

The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.

A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.

Was this resource helpful?

Yes No

Thank you for your input!

Email Updates

Stay informed about current research, online events, and more.

Meet the Experts

Larry Norton, M.D. is deputy physician-in-chief and director of Breast Cancer Programs at Memorial Sloan-Kettering Cancer Center in New York City.

Marisa Weiss, M.D. is a radiation oncologist specializing in breast cancer and the founder, president, and guiding force behind Breastcancer.org.

Breastcancer.org is a non-profit organization dedicated to providing information and community to those touched by this disease. Learn more about our commitment to providing complete, accurate, and private breast cancer information.

Breastcancer.org 7 East Lancaster Avenue, 3rd Floor Ardmore, PA 19003

View Mobile Site